Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and ATM Gene Mutations.

Clinical breast cancer - 1 Jun 2023

Fencer Maria G, Krupa Kelly A, Bleich Gabrielle C, Grumet Sherry, Eladoumikdachi Firas G, Kumar Shicha, Kowzun Maria J, Potdevin Lindsay B

Abstract excerpt

BACKGROUND: This study aims to capture clinical and surgical practice patterns of patients with deleterious mutations in partner and localizer of BRCA2 (PALB2), checkpoint kinase 2 (CHEK2) and ataxia telangiesctasia mutated (ATM) genes. MATERIALS AND METHODS: This study is a retrospective chart review of patients with PALB2, CHEK2 or ATM mutations. Patient demographics, testing indications, management decisions,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Checkpoint Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ataxia

Share to Ataxia Telangiectasia Mutated Proteins

Share to Fanconi Anemia Complementation Group N Protein

Share to Genetic Predisposition to Disease

Share to Mastectomy

Share to Mutation

Source

Identifiers

PMID: 36966080
DOI: 10.1016/j.clbc.2023.02.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and ATM Gene Mutations.PMID 36966080Read ↗

Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations.Semantic proximity Read ↗

Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.Semantic proximity Read ↗

Expectations of Surveillance for Non-BRCA Gene Mutation Carriers at Increased Risk for Breast Cancer.Semantic proximity Read ↗

Association of Moderate-Risk Breast Cancer Genes with Contralateral Prophylactic Mastectomy and Bilateral Disease.Semantic proximity Read ↗

Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Semantic proximity Read ↗

Pathogenic and likely pathogenic variants in PALB2 , CHEK2 , and other known breast cancer susceptibility genes among 1054 BRCA ‐negative Hispanics with breast cancerSemantic proximity Read ↗

Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing.Semantic proximity Read ↗

Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.Semantic proximity Read ↗

Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.Semantic proximity Read ↗

Breast Cancer Risk Modification in Women with Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2, and PALB2.Semantic proximity Read ↗

Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants.Semantic proximity Read ↗

Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.